Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Determine the Efficacy and Safety of Biphasic Remogliflozin Etabonate When Administered to Subjects With Type 2 Diabetes Mellitus

NCT02537470 is registered in ClinicalTrials.gov with BHV Pharma as lead sponsor.

NCT NCT02537470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02537470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Determine the Efficacy and Safety of Biphasic Remogliflozin Etabonate When Administered to Subjects With Type 2 Diabetes Mellitus
Lead sponsor
BHV Pharma
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2015
Completion date
August 31, 2016
Enrollment
191 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, type 2 diabetes mellitus